Welcome to our dedicated page for Exelixis news (Ticker: $EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Exelixis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Exelixis's position in the market.
Exelixis, Inc. (Nasdaq: EXEL) will participate in fireside chats at investor conferences in May, including BofA Securities Health Care Conference, Citizens JMP Life Sciences Conference, and RBC Capital Markets Global Healthcare Conference. The presentations will be webcast on www.exelixis.com with replay options available for at least 30 days.
Exelixis, Inc. (Nasdaq: EXEL) reported Q1 2024 financial results of $425M in total revenues, $379M from Cabozantinib Franchise U.S. Net Product Revenues. Restructuring expenses of $32.8M were recorded. GAAP Diluted EPS was $0.12, Non-GAAP Diluted EPS was $0.17. Exelixis focused on advancing pivotal trials, pipeline development, and label expansion for cabozantinib. The company maintained financial guidance for 2024. Positive clinical trial results were highlighted, and strategic priorities for 2024 were outlined. Exelixis also announced share repurchase program updates and key board member appointments.